JP2022510700A - 治療において使用するusp19阻害剤 - Google Patents
治療において使用するusp19阻害剤 Download PDFInfo
- Publication number
- JP2022510700A JP2022510700A JP2021532119A JP2021532119A JP2022510700A JP 2022510700 A JP2022510700 A JP 2022510700A JP 2021532119 A JP2021532119 A JP 2021532119A JP 2021532119 A JP2021532119 A JP 2021532119A JP 2022510700 A JP2022510700 A JP 2022510700A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- hydroxy
- phenyl
- oxo
- dihydropyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1819936.4 | 2018-12-06 | ||
| GBGB1819936.4A GB201819936D0 (en) | 2018-12-06 | 2018-12-06 | Therapeutic methods |
| GBGB1904341.3A GB201904341D0 (en) | 2019-03-28 | 2019-03-28 | Therapeutic methods |
| GB1904341.3 | 2019-03-28 | ||
| PCT/GB2019/053456 WO2020115500A1 (en) | 2018-12-06 | 2019-12-06 | Usp19 inhibitors for use in therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022510700A true JP2022510700A (ja) | 2022-01-27 |
| JP2022510700A5 JP2022510700A5 (cg-RX-API-DMAC7.html) | 2023-01-11 |
Family
ID=68887434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532119A Pending JP2022510700A (ja) | 2018-12-06 | 2019-12-06 | 治療において使用するusp19阻害剤 |
Country Status (12)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022535496A (ja) * | 2019-05-06 | 2022-08-09 | ヴァロ ヘルス インコーポレイテッド | Usp19の抑制 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202104097D0 (en) * | 2021-03-24 | 2021-05-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB202311227D0 (en) | 2023-07-21 | 2023-09-06 | Almac Discovery Ltd | Pharmaceutical compounds |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018020242A1 (en) * | 2016-07-26 | 2018-02-01 | Almac Discovery Limited | Pharmaceutical compounds |
| JP2021525220A (ja) * | 2018-01-31 | 2021-09-24 | アルマック・ディスカバリー・リミテッドAlmac Discovery Limited | 4−ヒドロキシピペリジン誘導体およびユビキチン特異的プロテアーゼ19(usp19)の阻害剤としてのその使用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO111096A0 (en) * | 1996-07-18 | 1996-08-08 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| WO2009072643A1 (en) | 2007-12-03 | 2009-06-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound and use thereof |
| CN104174021A (zh) * | 2013-05-22 | 2014-12-03 | 复旦大学附属华山医院 | 蛋白酶体抑制剂在制备治疗慢性低度炎症性疾病药物中的用途 |
| TWI698436B (zh) * | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶 |
| AU2018342089B2 (en) * | 2017-09-26 | 2024-07-11 | Dana-Farber Cancer Institute, Inc. | Novel USP7 inhibitors for treating multiple myeloma |
-
2019
- 2019-12-06 JP JP2021532119A patent/JP2022510700A/ja active Pending
- 2019-12-06 CN CN201980091404.7A patent/CN113395965A/zh active Pending
- 2019-12-06 AU AU2019393161A patent/AU2019393161A1/en not_active Abandoned
- 2019-12-06 KR KR1020217019978A patent/KR20210100127A/ko not_active Withdrawn
- 2019-12-06 SG SG11202105911PA patent/SG11202105911PA/en unknown
- 2019-12-06 CA CA3121422A patent/CA3121422A1/en active Pending
- 2019-12-06 MX MX2021006542A patent/MX2021006542A/es unknown
- 2019-12-06 EP EP19821175.7A patent/EP3890737B1/en active Active
- 2019-12-06 US US17/299,971 patent/US20220016115A1/en not_active Abandoned
- 2019-12-06 BR BR112021010645-6A patent/BR112021010645A2/pt not_active IP Right Cessation
- 2019-12-06 WO PCT/GB2019/053456 patent/WO2020115500A1/en not_active Ceased
-
2021
- 2021-06-03 IL IL283687A patent/IL283687A/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018020242A1 (en) * | 2016-07-26 | 2018-02-01 | Almac Discovery Limited | Pharmaceutical compounds |
| JP2021525220A (ja) * | 2018-01-31 | 2021-09-24 | アルマック・ディスカバリー・リミテッドAlmac Discovery Limited | 4−ヒドロキシピペリジン誘導体およびユビキチン特異的プロテアーゼ19(usp19)の阻害剤としてのその使用 |
Non-Patent Citations (2)
| Title |
|---|
| ACS MED. CHEM. LETT., vol. 9, JPN6024001751, 2018, pages 238 - 243, ISSN: 0005243422 * |
| DIABETOLOGIA, vol. 62, JPN6024001752, 1 November 2018 (2018-11-01), pages 136 - 146, ISSN: 0005243421 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022535496A (ja) * | 2019-05-06 | 2022-08-09 | ヴァロ ヘルス インコーポレイテッド | Usp19の抑制 |
| JP7733578B2 (ja) | 2019-05-06 | 2025-09-03 | ヴァロ ヘルス インコーポレイテッド | Usp19の抑制 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020115500A1 (en) | 2020-06-11 |
| AU2019393161A1 (en) | 2021-06-17 |
| EP3890737A1 (en) | 2021-10-13 |
| IL283687A (en) | 2021-07-29 |
| EP3890737B1 (en) | 2024-06-05 |
| CA3121422A1 (en) | 2020-06-11 |
| MX2021006542A (es) | 2021-07-07 |
| BR112021010645A2 (pt) | 2021-08-17 |
| KR20210100127A (ko) | 2021-08-13 |
| US20220016115A1 (en) | 2022-01-20 |
| CN113395965A (zh) | 2021-09-14 |
| SG11202105911PA (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7295169B2 (ja) | Btk阻害活性を有するピリミジン及びピリジン化合物を用いた癌の治療方法 | |
| JP5379787B2 (ja) | プロテインキナーゼの阻害剤 | |
| CN104837825B (zh) | 鲁顿酪氨酸激酶抑制剂 | |
| EA007063B1 (ru) | ПРОИЗВОДНЫЕ АМИНОБЕНЗАМИДОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОГЕНСИНТАЗА-КИНАЗЫ 3β; | |
| US10875863B2 (en) | RIPK2 inhibitors and method of treating cancer with same | |
| EA028057B1 (ru) | Производные аминопиримидина для применения в качестве модуляторов киназной активности | |
| JP2010525025A (ja) | プロテインキナーゼの阻害剤としての4,6−二置換アミノピリミジン誘導体 | |
| JP2018517672A (ja) | イソオキサゾリル置換イミダゾピリジン類 | |
| US20040009993A1 (en) | Pyridopyrimidinones derivatives as telomerase inhibitors | |
| CN106928231A (zh) | 一类新型的egfr野生型和突变型的激酶抑制剂 | |
| EP3890737B1 (en) | Usp19 inhibitors for use in a method of treating obesity, insulin resistance and type ii diabetes | |
| JP2021098691A (ja) | 核内受容体に対して活性の化合物 | |
| JP4422335B2 (ja) | グアニル酸シクラーゼ活性化剤としてのスルホニルアミノカルボン酸n−アリールアミド | |
| KR20160148679A (ko) | 나프티리딘디온 유도체 | |
| US20250084056A1 (en) | Substituted oxoisoindolinyl piperidine-2,6-dione compounds | |
| JP2013515766A (ja) | イマチニブジクロロ酢酸塩及びそれを含む抗癌剤組成物 | |
| JP5566879B2 (ja) | プロテインキナーゼの阻害剤 | |
| TW201022234A (en) | Pyrrolidines | |
| BRPI0618284A2 (pt) | derivado de pirazolo-[4,3-d]-pirimidin-5-il usado como inibidores de pde5 | |
| US20080153822A1 (en) | Methods of treating pain | |
| WO2020187292A1 (zh) | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 | |
| AU2024300899A1 (en) | Pharmaceutical compounds | |
| JP2005336173A (ja) | 骨粗鬆症治療剤 | |
| TW202615014A (zh) | 作為蛋白質酪氨酸磷酸酶抑制劑的含雙鍵取代的化合物及其應用 | |
| WO2026020014A1 (en) | Small molecule inhibitors of dna pkcs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221205 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240123 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240410 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240723 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20241008 |